Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 1Lung Neoplasms 1Lung Diseases 1Esophageal Squamous Cell Carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Cisplatin 8Radiotherapy 7Fluorouracil 6Neoadjuvant Therapy 4Irinotecan 4pembrolizumab 3Paclitaxel 3Gefitinib 3Carboplatin 3toripalimab 2spartalizumab 2Oxaliplatin 2Nivolumab 2Esophagectomy 2Docetaxel 2vandetanib 1tislelizumab 1sitravatinib 1ribociclib 1oblimersen 1nazartinib 1liposomal doxorubicin 1apatinib 1Surgical Procedures, Operative 1SGN-LIV1A 1Proton Therapy 1Pemetrexed 1Panitumumab 1Nutritional Support 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Esophageal Squamous Cell Carcinoma × sitravatinib × Clear all
NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

BeiGene

Phase 2 Terminated
96 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡